MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 52
Summary
- Conditions
- Malignant Glioma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: As of Amendment 12, patients enrolled in the phase II portion of this trial will no longer be randomized. These patients will undergo MLA followed by MK-3475 treatment.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02311582
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Principal Investigator: Jian L Campian, M.D., Ph.D. Washington University School of Medicine
Get Well Soon